title: Stereotactic radiotherapy for pediatric intracranial germ cell tumors.
abstract: OBJECTIVE
  Intracranial germ cell tumors are rare, radiosensitive tumors seen most commonly in the second and third decades of life. Radiotherapy alone has been the primary treatment modality for germinomas, and is used with chemotherapy for nongerminomatous tumors. Stereotactic radiotherapy techniques minimize the volume of surrounding normal tissue irradiated and, hence, the late radiation morbidity. This study reports our experience with stereotactic radiotherapy in this group of tumors.
  
  
  METHODS
  Between December 1992 and December 1998, 18 patients with intracranial germ cell tumors were treated with stereotactic radiotherapy. A total of 23 histologically proven tumors were treated. Thirteen patients had a histologic diagnosis of germinoma, and 5 patients had germinoma with nongerminomatous elements. Of those patients with a histologic diagnosis of germinoma, 5 had multiple midline tumors. The median age of the patients was 12.9 years (range, 5.6-17.5 years).
  
  
  RESULTS
  A boost using stereotactic radiotherapy was delivered to 19 tumors following whole-brain radiation in 8 cases and craniospinal radiation in 11 cases. Three tumors were treated with stereotactic radiotherapy to the tumor volume alone following chemotherapy, and 1 tumor received a boost using stereotactic radiosurgery following craniospinal radiation. A median dose of 2520 cGy (range, 1500-3600) cGy was given to the whole brain, and a median dose of 2160 (range, 2100-2600) cGy was given to the spinal field. The median boost dose to the tumor was 2600 (range, 2160-3600) cGy, given by stereotactic radiotherapy delivered to the 95% isodose line. At a median follow-up time of 40 (range, 12-73) months, no local or marginal recurrences were reported in patients with germinoma. Two patients with nongerminomatous tumors have relapsed. One had elevation of tumor markers only at 37 months following treatment, and the other had persistent disease following chemotherapy and radiation therapy. Eight patients documented pituitary-hypothalamic dysfunction; in 7 (87.5%) of these patients, the dysfunction was present before commencing radiotherapy. Four patients (22%) developed newly diagnosed diabetes insipidus following surgery. Three patients (17%) received antidepressant medication at follow-up.
  
  
  CONCLUSIONS
  Our series shows that stereotactic radiotherapy is achievable and well tolerated in this group of patients. Longer follow-up is required to fully assess the impact on long-term toxicity. Psychologic assessment of mood and affect should be performed as part of routine follow-up in this group of adolescent children.
authors.affiliation: Department of Radiation Oncology, Prince of Wales Hospital, Randwick, New South Wales, Australia.
authors.forename: Y
authors.initials: Y
authors.lastname: Zissiadis
authors.forename: S
authors.initials: S
authors.lastname: Dutton
authors.forename: M
authors.initials: M
authors.lastname: Kieran
authors.forename: L
authors.initials: L
authors.lastname: Goumnerova
authors.forename: R M
authors.initials: RM
authors.lastname: Scott
authors.forename: H M
authors.initials: HM
authors.lastname: Kooy
authors.forename: N J
authors.initials: NJ
authors.lastname: Tarbell
mesh_terms: D000293:Adolescent; D001932:Brain Neoplasms / Q000188:drug therapy / Q000601:surgery*; D002648:Child; D002675:Child, Preschool; D005500:Follow-Up Studies; D018237:Germinoma / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000601:surgery; D016634:Radiosurgery; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D016019:Survival Analysis